Compare · CYPH vs NVS
CYPH vs NVS
Side-by-side comparison of Cypherpunk Technologies Inc. (CYPH) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYPH and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $296.16B, about 1138.5x CYPH ($260.1M).
- NVS has been more active in the news (5 items in the past 4 weeks vs 4 for CYPH).
- NVS has more recent analyst coverage (25 ratings vs 1 for CYPH).
- Company
- Cypherpunk Technologies Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $260.1M
- $296.16B
- 1M return
- -
- +1.07%
- 1Y return
- -
- +21.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 5
- Recent ratings
- 1
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest CYPH
- Cypherpunk Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cypherpunk Technologies Reports Third Quarter 2026 Financial Results
- SEC Form 10-Q filed by Cypherpunk Technologies Inc.
- Cypherpunk Technologies to Report Third Quarter 2026 Financial Results on November 16, 2026
- SEC Form 4 filed by Cypherpunk Technologies Inc.
- SEC Form 4 filed by Cypherpunk Technologies Inc.
- SEC Form 3 filed by new insider Fabiano Amanda
- Director Martin Patricia A. sold $193,000 worth of shares (50,000 units at $3.86), decreasing direct ownership by 30% to 118,750 units (SEC Form 4)
- Director Oei Khing Djien sold $661,500 worth of shares (168,750 units at $3.92), closing all direct ownership in the company (SEC Form 4)
- Cypherpunk Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank